Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.
The relationship between coagulation cascade activation and glioma cell proliferation was examined. The human glioma cell lines T98G, TM-1 and normal human astrocyte cell strain (NHA) were examined. Using anti-tissue factor (TF) antibody, immunocytochemical detection of TF antigen was obtained in both cell lines and cell strain. TF antigen in cell lysates was also measured by enzyme linked immunosorbent assay (ELISA). In a one-stage clotting assay, T98G, TM-1 and NHA revealed procoagulant activity (PCA) in normal human plasma and factor VII deficient plasma. PCA in normal human plasma was significantly inhibited by both inhibitory anti-TF antibody and cysteine protease inhibitor HgCl2. This result indicates that T98G, TM-1 and NHA cells express not only TF but also cancer procoagulant (CP) at the same time. In a cell proliferation assay, thrombin induced proliferation in T98G and TM-1 cells in a dose-dependent fashion and in NHA cell in a bell-shaped fashion. This mitogenic stimulant was inhibited by the specific thrombin inhibitor hirudin. The combinations of coagulation factors II, V, and X with or without factor VII induced proliferation in T98G, TM-1, and NHA cells. The maximal mitogenic stimulatory effects were larger in glioma cells than in NHA. These mitogenic stimulatory effects were also inhibited by hirudin. Each coagulation factor on its own or in any other combination of coagulation factors had no proliferative effect. Thus, these mitogenic stimulatory effects were considered to be the effect of thrombin. In conclusion, T98G and TM-1 human glioma cells express two different types of procoagulants TF and CP. In the presence of coagulation factors, these glioma cells can generate thrombin and this thrombin generation is capable of inducing glioma cell proliferation in vitro.
Ogiichi
T
T
Department of Neurosurgery, Toyama Medical and Pharmaceutical University, Japan.
Hirashima
Y
Y
Nakamura
S
S
Endo
S
S
Kurimoto
M
M
Takaku
A
A
D000906:Antibodies / Q000494:pharmacology; D001790:Blood Physiological Phenomena; D002455:Cell Division / Q000502:physiology; D003546:Cysteine Endopeptidases / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005168:Factor VII Deficiency / Q000097:blood; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D015636:Magnesium Chloride / Q000494:pharmacology; D018613:Microscopy, Confocal; D009363:Neoplasm Proteins; D012016:Reference Values; D013917:Thrombin / Q000502:physiology*; D013925:Thromboplastin / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D014407:Tumor Cells, Cultured
D000906:Antibodies; D015853:Cysteine Proteinase Inhibitors; D009363:Neoplasm Proteins; D015636:Magnesium Chloride; D013925:Thromboplastin; D013917:Thrombin; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant